Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: To evaluate the progression rate of geographic atrophy (GA) and identify factors associated with GA expansion in eyes with reticular pseudodrusen (RPD) using fundus autofluorescence (FAF) photography.
Methods: A total of 28 eyes from 28 patients diagnosed with GA and RPD, who completed a 3-year follow-up, was included. The eyes underwent thorough examination with color fundus photography, FAF and near infrared (NIR) imaging, and spectral domain optical coherence tomography (SD OCT). The areas of atrophic lesions were quantified using FAF images at years 1, 2, and 3 employing a semi-automated software (Region Finder).
Results: The rate of increase in mean GA area in eyes with RPD was calculated to be 0.39 ± 0.21 mm per year over the 3-year period. The annual progression rate measured over three years showed a statistically significant increase each year. Univariate analysis revealed that subfoveal choroidal thickness (SFCT) and RPD distribution were independently associated with GA progression (P ≤ 0.037). In multivariate analysis, thin SFCT was the only significant factor linked to an increased rate of GA growth. The progression from extrafoveal GA to foveal GA was solely associated with the initial square root GA area.
Conclusion: These results offer valuable insights for the development of interventional strategies aimed at mitigating GA enlargement in this specific subgroup of patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12342254 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0329907 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Real-World Experience of Geographic Atrophy Treatment With Avacincaptad Pegol.
J Vitreoretin Dis
September 2025
Retina Group of Washington, Reston, VA, USA.
To present the first real-world safety data describing the clinical experience of geographic atrophy (GA) treatment with avacincaptad pegol in a large cohort. A retrospective, observational cohort study was conducted within the PRISM Vision Group by filtering for J codes for avacincaptad pegol from August 3, 2023, to October 10, 2024. The study included 461 eyes of 335 patients with GA who were treated with intravitreal avacincaptad pegol 2 mg (0.
View Article and Find Full Text PDFReal-World Experience with Intravitreal Pegcetacoplan for the Treatment of Geographic Atrophy in Age-Related Macular Degeneration.
Am J Ophthalmol
September 2025
Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA. Electronic address:
Purpose: To report on the real-world experience of using intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) in age-related macular degeneration (AMD).
Design: Retrospective interventional case series.
Methods: Eyes with symptomatic GA secondary to AMD were treated with 15mg of intravitreal pegcetacoplan and participated in an ongoing prospective swept-source optical coherence tomography angiography (SS-OCTA) imaging study.
Bilateral multiple retinal pigment epithelial detachments.
Doc Ophthalmol
September 2025
Department of Ophthalmology, Saitama Medical University Faculty of Medicine, 38 Moro-Hongo Moroyama-machi, Iruma-gun, Saitama, 350-0495, Japan.
Purpose: To report a rare case of bilateral idiopathic multifocal retinal pigment epithelial detachments (imfPEDs) and to describe the long-term morphological and functional changes observed over a 16-year follow-up period.
Methods: A 49-year-old woman was diagnosed with imfPEDs based on multimodal imaging, including optical coherence tomography (OCT), fluorescein angiography (FA), and fundus photography. Full-field electroretinograms (ffERGs) and multifocal ERGs (mfERGs) were recorded to assess retinal function.
Investigating Macular Tissue Integrity Index as a Novel Biomarker in Geographic Atrophy.
Ophthalmol Sci
June 2025
Retina Foundation of the Southwest, Dallas, Texas.
Purpose: The rate of geographic atrophy (GA) enlargement is commonly used as an outcome in clinical trials. However, this metric typically lacks specificity for central macular involvement and structure-function relationships. We propose a targeted approach in monitoring GA progression within the central macula, highlighting the limited benefit of including GA expansion beyond the 3-mm perifoveal zone when analyzing visual function.
View Article and Find Full Text PDFObjective: To assess the prevalences of subfoveal retinal pigment epithelium (RPE) loss versus subfoveal tissue proliferation as causes of vision loss in patients with late-stage age-related macular degeneration (AMD) or myopic macular atrophy.
Design: Population-based studies conducted in Russia, China, and India and histological examination of enucleated human globes.
Participants: The Russian Ural Eye and Medical Study ( = 5899 participants; age: ≥40 years), Ural Very Old Study ( = 1526; age: 85+ years), Beijing Eye Study ( = 3468; age: ≥40 years), and Central India Eye and Medical Study ( = 4711) were conducted in rural and urban regions in Bashkortostan/Russia, Beijing/China, and Nagpur/India, respectively.